Amplification or mutation of fibroblast growth factor receptor (FGFR) has been reported in endometrial cancers with a frequency of 10% and FGFR2 may represent a novel molecular target for the treatment of endometrial cancer [5]. The gene discussed is FGFR2; the disease is endometrial cancer.